Syncom Formulation (India) Ltd. (IN:SYNCOMF)
:SYNCOMF
Want to see IN:SYNCOMF full AI Analyst Report?
SYNCOMF Stock Chart & Stats
₹13.98
-₹0.26(-1.33%)
At close: 4:00 PM EST
₹13.98
-₹0.26(-1.33%)
Day’s Range― - ―
52-Week Range₹10.21 - ₹23.46
Previous CloseN/A
Volume2.15M
Average Volume (3M)249.72K
Market Cap
₹12.96B
Enterprise Value₹13.19B
Total Cash (Recent Filing)₹1.45B
Total Debt (Recent Filing)₹6.97M
Price to Earnings (P/E)17.7
Beta1.56
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.69
Shares Outstanding940,000,000
10 Day Avg. Volume232,913
30 Day Avg. Volume249,719
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)4.34
Price to Sales (P/S)3.19
P/FCF Ratio110.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue & Margin ExpansionExceptionally strong revenue growth paired with materially higher gross and EBITDA margins implies expanding product adoption and improving operational leverage. Over the next 2–6 months, sustained top-line momentum and margin expansion support durable earnings power and internal funding for capacity or product investments.
Strong Balance Sheet / Low LeverageA very low debt load and high equity ratio provide financial flexibility to absorb shocks, invest in growth, or pursue M&A without straining liquidity. This conservative capital structure reduces refinancing risk and makes the business more resilient to cyclical pressures over a multi-month horizon.
Recovering Free Cash FlowReturn to positive free cash flow demonstrates the company's ability to convert operations into spendable cash, enabling capex, debt reduction, or reinvestment. While conversion remains moderate, the FCF recovery signals improving cash generation that supports durable operating flexibility and capital allocation.
Bears Say
Moderate Cash ConversionLess than half of reported net income converting to operating cash indicates working-capital drag or non-cash earnings components. Persistently weak conversion can constrain self-funded growth, elevate refinancing or working-capital needs, and expose the company to liquidity pressure over coming months.
Margin Sensitivity To API Costs & UtilizationMargins depend on input commodity costs, plant utilization and compliance execution. Volatility in API or packaging prices or suboptimal capacity use can quickly erode recent margin gains, making earnings and cash generation vulnerable absent disciplined procurement and utilization improvements.
Limited Forward Visibility / GuidanceAbsence of formal guidance or disclosed operational highlights reduces investor visibility into sales cadence, product mix and capital plans. This lack of transparency increases execution risk and makes it harder to assess whether strong recent results are sustainable across the next several reporting periods.
Syncom Formulation (India) Ltd. News
SYNCOMF FAQ
What was Syncom Formulation (India) Ltd.’s price range in the past 12 months?
Syncom Formulation (India) Ltd. lowest stock price was ₹10.21 and its highest was ₹23.46 in the past 12 months.
What is Syncom Formulation (India) Ltd.’s market cap?
Syncom Formulation (India) Ltd.’s market cap is ₹12.96B.
When is Syncom Formulation (India) Ltd.’s upcoming earnings report date?
Syncom Formulation (India) Ltd.’s upcoming earnings report date is May 28, 2026 which is in 22 days.
How were Syncom Formulation (India) Ltd.’s earnings last quarter?
Syncom Formulation (India) Ltd. released its earnings results on Feb 12, 2026. The company reported ₹0.201 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.201.
Is Syncom Formulation (India) Ltd. overvalued?
According to Wall Street analysts Syncom Formulation (India) Ltd.’s price is currently Overvalued.
Does Syncom Formulation (India) Ltd. pay dividends?
Syncom Formulation (India) Ltd. pays a Notavailable dividend of ₹0.03 which represents an annual dividend yield of N/A. See more information on Syncom Formulation (India) Ltd. dividends here
What is Syncom Formulation (India) Ltd.’s EPS estimate?
Syncom Formulation (India) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Syncom Formulation (India) Ltd. have?
Syncom Formulation (India) Ltd. has 940,000,000 shares outstanding.
What happened to Syncom Formulation (India) Ltd.’s price movement after its last earnings report?
Syncom Formulation (India) Ltd. reported an EPS of ₹0.201 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.282%.
Which hedge fund is a major shareholder of Syncom Formulation (India) Ltd.?
Currently, no hedge funds are holding shares in IN:SYNCOMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Syncom Formulation (India) Ltd.
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also provides histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it engages in the trading of commodities and renting of properties. Further, the company exports its products. It offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.
Technical Analysis
GRP Ltd
―
Knowledge Marine & Engineering Works Limited
―
Media Matrix Worldwide Limited
―
Updater Services Limited
―
Uniparts India Ltd.
―